安科姚建平：创新引领企业高质量发展

Core Viewpoint - Anke Biopharma aims for high-quality development through innovation, focusing on a strategic layout that includes biopharmaceuticals, traditional Chinese medicine, and precision medicine, while actively exploring mRNA technology, ADC, oncolytic viruses, cell therapy, and gene therapy [2][4]. Financial Performance - In the first three quarters of 2025, Anke Biopharma reported a revenue of 1.963 billion yuan, representing a year-on-year increase of 2.15%. The net profit attributable to shareholders was 551 million yuan, a decrease of 6.48%. R&D expenses amounted to 145 million yuan, reflecting a year-on-year growth of approximately 12.4% [3]. Strategic Development - Anke Biopharma's strategic goal is to achieve a valuation, revenue, and profit of 10 billion yuan each, encapsulated in the phrase "100 billion Anke, 100-year Anke" [2]. - The company has a history of innovation since its establishment, transitioning from a state-owned enterprise to a publicly listed company, with significant reforms occurring in 1995, 1996, and 2000 [3]. R&D Focus - Anke Biopharma invests nearly 10% of its annual revenue into R&D, emphasizing innovation in product development, talent acquisition, and research investment [4]. - The company’s product portfolio includes biopharmaceuticals, traditional Chinese medicine, small molecule drugs, peptide drugs, and cell immunotherapy [4]. AI Integration - The integration of AI in drug development is highlighted, with potential to significantly reduce the time for drug discovery and clinical research, from five years to one year for large molecules and from five to eight years to three to five years for clinical studies [5]. - The establishment of the Anke Biopharma (Shanghai) Innovation Research Institute aims to enhance R&D capabilities and attract high-end talent, addressing current R&D bottlenecks and fostering innovation in drug development [5].